Passage BIO, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Passage BIO, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.52M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($64.77M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($102.06M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($136.13M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($185.39M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($112.23M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($45.63M) | Mar 3, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.30M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($70.40M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($108.39M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($138.39M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($185.73M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($112.90M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($37.19M) | Mar 3, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.28M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $40.18M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $61.42M | Mar 4, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($31.51M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($47.96M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($78.26M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($118.21M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($126.88M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($80.52M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($39.90M) | Mar 3, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.28M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $102.41M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $150.55M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $243.55M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $355.08M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $328.01M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $178.61M | Mar 3, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.53M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $41.15M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $39.26M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $42.18M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $36.42M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $23.29M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $4.26M | Mar 3, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.76M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $61.26M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $111.28M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $201.37M | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $318.66M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $304.71M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | ($56.25M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | ($12.17M) | Mar 3, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($704.76M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($659.24M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($594.47M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($492.41M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($356.28M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($170.90M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($58.66M) | Mar 3, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.30M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $37.57M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $21.71M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $34.60M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $128.97M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $135.00M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $158.87M | Mar 3, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (14) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (21) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 3, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (14) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (21) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 3, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.18M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 3.16M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 54.94M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 54.61M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 54.24M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | 45.61M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 4.29M | Mar 3, 2021 |